Every 10-Q that SIGA Technologies, Inc. (SIGA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SIGA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SIGA filings page.
SIGA Technologies reported Q2 2026 revenue of $41.0 million, down from $81.1 million a year earlier, as U.S. government purchases of oral TPOXX slowed and sales shifted toward IV TPOXX and new international orders. Net income was $12.5 million versus $35.5 million, with lower cost of sales and SG&A partly offsetting the revenue decline.
For the first half of 2026, revenue was $47.2 million and net income $9.0 million. Cash and cash equivalents were $117.6 million, and a special cash dividend of $0.60 per share (about $43.9 million) was paid. Results remain concentrated in government contracts, notably the BARDA agreement providing up to approximately $630 million of potential payments. Management notes an effective tax rate influenced by currently forecasted full‑year losses based on orders received to date.
SIGA Technologies, Inc. reported a challenging first quarter of 2026, posting a net loss of $3.5 million compared with a loss of $0.4 million a year earlier as revenue declined and costs rose. Total revenue fell to $6.2 million from $7.0 million, mainly because there were no international TPOXX® product sales in 2026 after a $5.8 million shipment to one country in 2025. U.S. revenue was driven by BARDA-related work, including $1.2 million of IV TPOXX® sales and $2.3 million of reimbursed manufacturing technology transfer services.
Operating expenses increased to $11.6 million from $9.3 million, with higher cost of sales tied to technology transfer and IV TPOXX® deliveries, and modestly higher R&D spending related in part to the European mpox referral process. Cash and cash equivalents remained strong at $145.6 million, even after net operating cash use of $8.7 million in the quarter. Stockholders’ equity declined to $151.6 million, largely reflecting a $0.60-per-share special cash dividend of about $43.9 million declared in March 2026 and paid in April.
SIGA Technologies (SIGA) reported Q3 2025 results showing lower quarterly activity amid timing of product deliveries. Revenue was $2.62 million, down from $10.01 million a year ago, with no point‑in‑time product delivery recognized in the quarter and $1.73 million from research and development services.
The quarter posted a net loss of $6.37 million versus net income of $1.34 million last year, reflecting higher self‑funded R&D and lower sales. Year to date, performance remains strong: nine‑month revenue was $90.78 million (vs. $57.25 million) and net income was $28.71 million (vs. $13.45 million). Cash and cash equivalents were $171.96 million as of September 30, 2025, after paying a $0.60 per share special dividend on May 15, 2025.
Under the 19C BARDA Contract, the company cites up to approximately $630 million of contemplated payments, with $79.1 million of 2025 revenue recognized at a point in time through September 30. The EMA initiated a referral to review Tecovirimat‑SIGA following mixed mpox trial readouts; approvals in other markets remain as stated. As of October 24, 2025, 71,611,302 shares were outstanding.